NCT02528357
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02528357
Title GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
colorectal cancer
Advanced Solid Tumor
sarcoma
urinary bladder cancer
head and neck squamous cell carcinoma
triple-receptor negative breast cancer
lung non-small cell carcinoma
melanoma
Therapies
GSK3174998
Pembrolizumab
Age Groups: adult
Covered Countries USA | NLD | FRA | CAN

Facility Status City State Zip Country Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site New York New York 10016 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Houston Texas 77030 United States Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
GSK Investigational Site Villejuif 94805 France Details
GSK Investigational Site Amsterdam 1066 CX Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field